Related Experiment Video
Updated: Feb 11, 2026

Microbioreactor-Based Production of Anchorage-Dependent Mesenchymal Stromal Cells Primed for Acute Respiratory Distress Syndrome
Published on: December 12, 2025
Mesenchymal Stromal Cell Therapy for Respiratory Complications of Extreme Prematurity
Bernard Thébaud1,2,3,4
1Sinclair Centre for Regenerative Medicine, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
Insights
Mesenchymal stromal cell therapy shows promise for preventing and repairing lung damage in extremely preterm infants. Clinical trials are evaluating its safety and effectiveness for bronchopulmonary dysplasia.
Area of Science:
- Neonatal Medicine
- Regenerative Medicine
- Pulmonology
Background:
- Bronchopulmonary dysplasia (BPD) is a primary complication in extremely preterm infants.
- Stem cell therapies are emerging as potential treatments for organ damage in this population.
- Mesenchymal stromal cells (MSCs) show significant promise based on preclinical neonatal lung injury models.
Purpose of the Study:
- To review the rationale for using MSCs in preterm infants at risk for BPD.
- To summarize current preclinical and early clinical evidence.
- To identify knowledge gaps for optimizing MSC therapy.
Main Methods:
- Review of preclinical studies in animal models of neonatal lung injury.
- Analysis of early-phase clinical trial data on MSC safety and feasibility.
- Synthesis of current research on MSC mechanisms.
Main Results:
- Promising preclinical data supports MSCs for neonatal lung injury.
- Early clinical trials are investigating MSC safety and feasibility in preterm infants.
- Further research is needed to fully understand MSC efficacy and repair potential.
Conclusions:
- MSCs represent a leading cell therapy candidate for BPD prevention and treatment.
- Clinical translation requires addressing safety, efficacy, and optimal application strategies.
- Harnessing the full therapeutic potential of MSCs is crucial for improving outcomes in extremely preterm infants.
Abstract:
Bronchopulmonary dysplasia remains the main complication of extreme preterm birth. Research over the past 10 years suggests the potential for stem cell-based therapies to prevent and/or restore organ damage in extreme preterm infants. Mesenchymal stromal cells, in particular, have advanced as the forerunner among various cell therapies based on very promising preclinical studies in animal models of neonatal lung injury. Early phase clinical trials are now underway to determine the safety and feasibility of this cell therapy in preterm infants at risk of developing bronchopulmonary dysplasia. This review will summarize the current rationale for testing mesenchymal stromal cells in this patient population and highlight the gaps in our knowledge to safely harness the full repair potential of cell-based therapies.
Related Concept Videos
Mesenchymal Stem Cells
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Hemodialysis II: Procedure and Complications
Absolute and Local Extreme Values
Anatomy of Respiratory System II: Lower Respiratory Tract
The Larynx
It is located between the pharynx and the trachea, acts as a passageway for air, and hosts several critical structures, such as the epiglottis, vocal cords, and glottis. The epiglottis acts as a gateway, guiding food to the...
Gene Therapy

